Drug Safety is A Key Priority at the Center for Drug Evaluation and Research

The Drug Safety Priorities 2022 report is the eighth annual report detailing CDER’s key safety programs and activities, and illustrating the depth and versatility of drug safety initiatives across the Center and the FDA.  The report features the many ways in which CDER has continued to be involved in promoting and protecting public health during the ongoing SARS-CoV-2 coronavirus (COVID-19) pandemic, and the ongoing activities to address the national drug overdose crisis, including through the establishment of FDA’s Overdose Prevention Framework.  Other safety-related reports issued earlier, all available below, describe actions CDER has taken in recent years to enhance the quality, accountability, and timeliness of its pre- and post-market drug safety decisions—activities that form the foundation for the interdisciplinary scientific teamwork that is a hallmark of FDA’s drug safety oversight today.